DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Moulder-Thompson S, Borges VF, Baetz TD. et al.
Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
Clin Cancer Res 2017;
23: 3529-3536
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.